Abstract:: It is widely known that liver cirrhosis, regardless of the etiologies is accompanied by severe hemodynamic changes. The principal pathophysiological mechanisms are the hyperdynamic circulation with increased cardiac output, heart rate along with reduced systemic vascular resistance. Thus, counteractive mechanisms may develop that eventually lead to systolic as well as diastolic dysfunction and rhythm disturbances, in order to keep a steady homeostasis in the human body. : Literally, blunted contractile responsiveness to physical or pharmacological stress, impaired diastolic relaxation and electrophysiological changes, primarily QT interval prolongation, do occur progressively in a cirrhotic patient with no known preexisting cardiac disease. This condition is identified as cirrhotic cardiomyopathy (CCM), an entity different from that seen in alcoholic cardiac muscle disease. : For the past decades, clinicians did study and attempt to understand the pathophysiology and clinical significance of this process. Indeed, various factors have been identified acting at the molecular and cellular level. : Electrocardiography, echocardiography and various serum biomarkers are the main tools that help healthcare practitioners to point to the correct diagnosis. : Noteworthy, the subjects that suffer from cirrhotic cardiomyopathy may progress to heart failure during invasive procedures such as surgery, insertion of a transjugular intrahepatic portosystemic shunting (TIPS) and liver transplantation. Besides, several studies have illustrated that CCM is a contributing factor, or even a precipitant, of hepatorenal syndrome (HRS), a conceivable reversible kidney failure in patients with liver cirrhosis and ascites. : The treatment is the same as it is in the patients with liver cirrhosis and heart failure and there is no particular treatment for cirrhotic cardiomyopathy. Hence, it is of utmost importance to clearly comprehend the pathophysiology of this disease in order to design more accurate diagnostic tools and definitive treatments in a way to prevent the complications of cirrhosis and overt heart failure. : The objective of this review is to describe in a comprehensive way the pathological alterations that occur in the cardiovascular system of cirrhotic patients. It will also point the limitations that remain in the diagnosis and treatment strategies and more importantly, this review will alert the clinicians in the modern era to further observe and record additional pathological changes in this subset of patients.

B-type Natriuretic Peptide and Cirrhotic Cardiomyopathy

Rapid Bedside Assay of B - Type Natriuretic Peptide in Early Diagnosis of Heart Failure

Relationship between the extent of coronary artery lesions and plasma brain natriuretic peptide

An Elevated Level of BNP in Plasma is Related to the Development of Good Collateral Circulation in Coronary Artery Disease

BNP levels and its influencing factors in patients with acute coronary syndrome

Brain Natriuretic Peptide and Optimal Management of Heart Failure.

Correlation Between B Type Natriuretic Peptide And Metabolic Risk Factors

Plasma Concentration of Brain Natriuretic Peptide and Heart Dysfunction

Corelation Between Plasma N-terminal ProBNP(NT-proBNP) and Cardiac Dysfunction

Plasma Brain Natriuretic Peptide Levels in the Diagnosis of Heart Failure

N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE (NT-PROBNP): A POTENTIAL DIAGNOSTIC BIOMARKER FOR PREDICTING CARDIAC DYSFUNCTION IN PATIENTS WITH LIVER DISEASES

Brain Natriuretic Peptide: A Potential Indicator of Cardiomyogenesis after Autologous Mesenchymal Stem Cell Transplantation?

B-type Natriuretic Peptide Protect Cardiomyocytes at Reperfusion Via Mitochondrial Calcium Uniporter

E0677 Increased Plasma NTerminal Probtype Natriuretic Peptide in Patients with Hepatitis C Virus Infection

Levels of Brain Natriuretic Peptide Are Associated with Peripheral Arterial Disease in Subjects with Type-2 Diabetes Mellitus

Use of B-type Natriuretic Peptide in Evaluation of Early Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome.

Prevalence of cirrhotic cardiomyopathy and its relationship with serum pro-brain natriuretic peptide, hepatorenal syndrome, spontaneous bacterial peritonitis, and mortality

B-Type Natriuretic Peptides and Echocardiographic Measures of Cardiac Structure and Function

Cirrhotic Cardiomyopathy: The Interplay Between Liver and Cardiac Muscle. How Does the Cardiovascular System React When the Liver is Diseased?

B-Type Natriuretic Peptide-Induced Cardioprotection Against Reperfusion is Associated with Attenuation of Mitochondrial Permeability Transition

The biomarker N-terminal pro-brain natriuretic peptide and liver diseases.